DVA - DaVita
151.85
| Index: | S&P 500 | P/E: | 16.37 | EPS (ttm): | 9.28 | Insider Own: | 4.49% | Shs Outstand: | 82.62M | Perf Week: | -0.58% |
| Market Cap: | 12.82B | Forward P/E: | 13.37 | EPS next Y: | 11.36 | Insider Trans: | -5.46% | Shs Float: | 78.32M | Perf Month: | -5.92% |
| Income(ttm): | 827.68M | PEG: | 0.91 | EPS next Q: | 2.14 | Inst Own: | 92.46% | Short Float: | 4.82% | Perf Quarter: | -6.02% |
| Revenue(ttm): | 12.67B | P/S: | 1.01 | EPS this Y: | 14.48% | Inst Trans: | -3.37% | Short Ratio: | 4.83 | Perf Half Y: | 5.54% |
| Book/sh: | 4.68 | P/B: | 32.44 | EPS next Y: | 17.13% | ROA: | 4.81% | Short Interest: | 3.78M | Perf Year: | 46.19% |
| Cash/sh: | 13.98 | P/C: | 10.86 | EPS next 5Y: | 17.90% | ROE: | 104.38% | 52W Range: | 103.40 - 169.51 | Perf YTD: | 44.95% |
| Dividend Est.: | - | P/FCF: | 9.00 | EPS past 5Y: | 51.82% | ROI: | 6.96% | 52W High: | -10.42% | Beta: | 0.92 |
| Dividend TTM: | - | Quick Ratio: | 1.33 | Sales past 5Y: | 1.27% | Gross Margin: | 26.92% | 52W Low: | 46.86% | ATR (14): | 4.13 |
| Dividend Ex-Date: | - | Current Ratio: | 1.37 | EPS Y/Y TTM: | 45.46% | Oper. Margin: | 14.88% | RSI (14): | 43.24 | Volatility: | 3.13% 2.38% |
| Employees: | 70000 | Debt/Eq: | 31.54 | Sales Y/Y TTM: | 6.34% | Profit Margin: | 6.53% | Recom: | 2.91 | Target Price: | 163.00 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 29.73 | EPS Q/Q: | -4.59% | Payout: | 0.00% | Rel Volume: | 2.28 | Prev Close: | 147.54 |
| Sales Surprise: | 0.50% | EPS Surprise: | -4.91% | Sales Q/Q: | 4.56% | Earnings: | Oct 29 AMC | Avg Volume: | 782.51K | Price: | 151.85 |
| SMA20: | -3.99% | SMA50: | -3.22% | SMA200: | 3.63% | Undervalued: 7.34% | Volume: | 1,783,431 | Change: | 2.92% | |
Graham Classic formula value: 369.15
(P/E=8 * 1g) Min value: 215.83
(current P/E * 2g) Max value: 434.74
Average value: 339.91
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.